Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

Science Translational Medicine

Volumn 9, Issue 374, 2017, Pages

  Qasim, Waseem ^a,b   Zhan, Hong ^a   Samarasinghe, Sujith ^b   Adams, Stuart ^b   Amrolia, Persis ^a,b   Stafford, Sian ^a   Butler, Katie ^a   Rivat, Christine ^a   Wright, Gary ^b   Somana, Kathy ^b   Ghorashian, Sara ^a   Pinner, Danielle ^b   Ahsan, Gul ^b   Gilmour, Kimberly ^b   Lucchini, Giovanna ^b   Inglott, Sarah ^b   Mifsud, William ^b   Chiesa, Robert ^b   Peggs, Karl S ^c   Chan, Lucas ^d   Farzeneh, Farzin ^d   Thrasher, Adrian J ^a   Vora, Ajay ^e   Pule, Martin ^c   Veys, Paul ^a   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ASPARAGINASE; BLINATUMOMAB; CD19 ANTIGEN; CD52 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LENTIVIRUS VECTOR; MIXED LINEAGE LEUKEMIA PROTEIN; PREDNISOLONE; RITUXIMAB; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; THIOTEPA; THYMOCYTE ANTIBODY; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; TREOSULFAN; VINCRISTINE; CD52 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CELL ENGINEERING; COMPASSIONATE USE; FEMALE; GENE EDITING; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN CELL; INFANT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHOCYTE DEPLETION; MINIMAL RESIDUAL DISEASE; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; SKIN GRAFT VERSUS HOST REACTION; T LYMPHOCYTE; UNRELATED DONORS; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; CYTOLOGY; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LENTIVIRUS; METABOLISM; REMISSION; STEM CELL TRANSPLANTATION; TUMOR RECURRENCE;

ALEMTUZUMAB; ANTIGENS, CD19; CD52 ANTIGEN; COMPASSIONATE USE TRIALS; FEMALE; GENE EDITING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LENTIVIRUS; NEOPLASM RECURRENCE, LOCAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES; TRANSCRIPTION ACTIVATOR-LIKE EFFECTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 85011392403     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaj2013     Document Type: Article

References (26)

1. P. Tebas, D. Stein, W. W. Tang, I. Frank, S. Q. Wang, G. Lee, S. K. Spratt, R. T. Surosky, M. A. Giedlin, G. Nichol, M. C. Holmes, P. D. Gregory, D. G. Ando, M. Kalos, R. G. Collman, G. Binder-Scholl, G. Plesa, W.-T. Hwang, B. L. Levine, C. H. June, Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901-910 (2014).
2. M. Kalos, B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp, A. Bagg, C. H. June, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
3. D. L. Porter, B. L. Levine, M. Kalos, A. Bagg, C. H. June, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
4. S. L. Maude, N. Frey, P. A. Shaw, R. Aplenc, D. M. Barrett, N. J. Bunin, A. Chew, V. E. Gonzalez, Z. Zheng, S. F. Lacey, Y. D. Mahnke, J. J. Melenhorst, S. R. Rheingold, A. Shen, D. T. Teachey, B. L. Levine, C. H. June, D. L. Porter, S. A. Grupp, Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014).
5. A. L. Garfall, M. V. Maus, W.-T. Hwang, S. F. Lacey, Y. D. Mahnke, J. J. Melenhorst, Z. Zheng, D. T. Vogl, A. D. Cohen, B. M. Weiss, K. Dengel, N. D. Kerr, A. Bagg, B. L. Levine, C. H. June, E. A. Stadtmauer, Chimeric antigen receptor t cells against cd19 for multiple myeloma. N. Engl. J. Med. 373, 1040-1047 (2015).
6. D. L. Porter, W.-T. Hwang, N. V. Frey, S. F. Lacey, P. A. Shaw, A. W. Loren, A. Bagg, K. T. Marcucci, A. Shen, V. Gonzalez, D. Ambrose, S. A. Grupp, A. Chew, Z. Zheng, M. C. Milone, B. L. Levine, J. J. Melenhorst, C. H. June, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).
7. D. W. Lee, J. N. Kochenderfer, M. Stetler-Stevenson, Y. K. Cui, C. Delbrook, S. A. Feldman, T. J. Fry, R. Orentas, M. Sabatino, N. N. Shah, S. M. Steinberg, D. Stroncek, N. Tschernia, C. Yuan, H. Zhang, L. Zhang, S. A. Rosenberg, A. S. Wayne, C. L. Mackall, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 385, 517-528 (2015).
8. J. N. Kochenderfer, S. A. Rosenberg, Chimeric antigen receptor-modified T cells in CLL.N. Engl. J. Med. 365, 1937-1938 (2011).
9. S. A. Grupp, M. Kalos, D. Barrett, R. Aplenc, D. L. Porter, S. R. Rheingold, D. T. Teachey, A. Chew, B. Hauck, J. F. Wright, M. C. Milone, B. L. Levine, C. H. June, Chimeric antigen receptor-Modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
10. J. N. Kochenderfer, M. E. Dudley, R. O. Carpenter, S. H. Kassim, J. J. Rose, W. G. Telford, F. T. Hakim, D. C. Halverson, D. H. Fowler, N. M. Hardy, A. R. Mato, D. D. Hickstein, J. C. Gea-Banacloche, S. Z. Pavletic, C. Sportes, I. Maric, S. A. Feldman, B. G. Hansen, J. S. Wilder, B. Blacklock-Schuver, B. Jena, M. R. Bishop, R. E. Gress, S. A. Rosenberg, Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122, 4129-4139 (2013).
11. J. N. Brudno, R. P. T. Somerville, V. Shi, J. J. Rose, D. C. Halverson, D. H. Fowler, J. C. Gea-Banacloche, S. Z. Pavletic, D. D. Hickstein, T. L. Lu, S. A. Feldman, A. T. Iwamoto, R. Kurlander, I. Maric, A. Goy, B. G. Hansen, J. S. Wilder, B. Blacklock-Schuver, F. T. Hakim, S. A. Rosenberg, R. E. Gress, J. N. Kochenderfer, Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34, 1112-1121 (2016).
12. P. Muranski, A. Boni, C. Wrzesinski, D. E. Citrin, S. A. Rosenberg, R. Childs, N. P. Restifo, Increased intensity lymphodepletion and adoptive immunotherapy-How far can we go? Nat. Clin. Pract. Oncol. 3, 668-681 (2006).
13. S. Chakrabarti, G. Hale, H. Waldmann, Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: Where do we go from here? Transplant. Proc. 36, 1225-1227 (2004).
14. L. Poirot, B. Philip, C. Schiffer-Mannioui, D. Le Clerre, I. Chion-Sotinel, S. Derniame, P. Potrel, C. Bas, L. Lemaire, R. Galetto, C. Lebuhotel, J. Eyquem, G. W. Cheung, A. Duclert, A. Gouble, S. Arnould, K. Peggs, M. Pule, A. M. Scharenberg, J. Smith, Multiplex genome-edited T-cell manufacturing platform for "off-the-shelf" adoptive T-cell immunotherapies. Cancer Res. 75, 3853-3864 (2015).
15. M. Schumm, P. Lang, W. Bethge, C. Faul, T. Feuchtinger, M. Pfeiffer, W. Vogel, V. Huppert, R. Handgretinger, Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy 15, 1253-1258 (2013).
16. B. Philip, E. Kokalaki, L. Mekkaoui, S. Thomas, K. Straathof, B. Flutter, V. Marin, T. Marafioti, R. Chakraverty, D. Linch, S. A. Quezada, K. S. Peggs, M. Pule, A highly compact epitopebased marker/suicide gene for easier and safer T-cell therapy. Blood 124, 1277-1287 (2014).
17. C. L. Batlevi, E. Matsuki, R. J. Brentjens, A. Younes, Novel immunotherapies in lymphoid malignancies. Nat. Rev. Clin. Oncol. 13, 25-40 (2015).
18. J. N. Brudno, J. N. Kochenderfer, Toxicities of chimeric antigen receptor T cells: Recognition and management. Blood 127, 3321-3330 (2016).
19. A. Bertaina, P. Merli, S. Rutella, D. Pagliara, M. E. Bernardo, R. Masetti, D. Pende, M. Falco, R. Handgretinger, F. Moretta, B. Lucarelli, L. P. Brescia, G. Li Pira, M. Testi, C. Cancrini, N. Kabbara, R. Carsetti, A. Finocchi, A. Moretta, L. Moretta, F. Locatelli, HLA-haploidentical stem cell transplantation after removal of ab+ T and B cells in children with nonmalignant disorders. Blood 124, 822-826 (2014).
20. E. Jacoby, Y. Yang, H. Qin, C. D. Chien, J. N. Kochenderfer, T. J. Fry, Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood 127, 1361-1370 (2016
21. I. Kopolovic, J. Ostro, H. Tsubota, Y. Lin, C. M. Cserti-Gazdewich, H. A. Messner, A. K. Keir, N. DenHollander, W. S. Dzik, J. Callum, A systematic review of transfusion-associated graft-versus-host disease. Blood 126, 406-414 (2015).
22. R. Gardner, D. Wu, S. Cherian, M. Fang, L.-A. Hanafi, O. Finney, H. Smithers, M. C. Jensen, S. R. Riddell, D. G. Maloney, C. J. Turtle, Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127, 2406-2410 (2016).
23. V. G. Bhoj, D. Arhontoulis, G. Wertheim, J. Capobianchi, C. A. Callahan, C. T. Ellebrecht, A. E. Obstfeld, S. F. Lacey, J. J. Melenhorst, F. Nazimuddin, W.-T. Hwang, S. L. Maude, M. A. Wasik, A. Bagg, S. Schuster, M. D. Feldman, D. L. Porter, S. A. Grupp, C. H. June, M. C. Milone, Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T cell therapy. Blood 128, 360-370 (2016)
24. W.-L. Di, J. E. Mellerio, C. Bernadis, J. Harper, A. Abdul-Wahab, S. Ghani, L. Chan, M. Martinez-Queipo, H. Hara, A.-M. McNicol, F. Farzaneh, J. McGrath, A. Thrasher, W. Qasim, Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome. Hum. Gene Ther. Clin. Dev. 24, 182-190 (2013).
25. C. Georgiadis, F. Syed, A. Petrova, A. Abdul-Wahab, S. M. Lwin, F. Farzaneh, L. Chan, S. Ghani, R. A. Fleck, L. Glover, J. R. McMillan, M. Chen, A. J. Thrasher, J. A. McGrath, W.-L. Di, W. Qasim, Lentiviral engineered fibroblasts expressing codon optimized COL7A1 restore anchoring fibrils in RDEB. J. Invest. Dermatol. 136, 284-292 (2015).
26. A. Hassan, P. Lee, P. Maggina, J. H. Xu, D. Moreira, M. Slatter, Z. Nademi, A. Worth, S. Adams, A. Jones, C. Cale, Z. Allwood, K. Rao, R. Chiesa, P. Amrolia, H. Gaspar, E. G. Davies, P. Veys, A. Gennery, W. Qasim, Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency. J. Allergy Clin. Immunol. 133, 1660-1666 (2014).